Liquidia reported strong third quarter results with $51.7 million in product revenue from YUTREPIA and a significant improvement in net loss, achieving positive operating income for the first time.

Liquidia's Q2 2025 results reflect a pivotal period marked by the commercial launch of YUTREPIA. Revenue grew significantly year-over-year, although expenses tied to commercialization efforts and litigation led to a larger net loss compared to Q2 2024.

Liquidia reported a net loss of $38.4 million for the first quarter of 2025, an increase from the $30.1 million net loss in the same period last year. Revenue remained relatively stable at $3.1 million, primarily from their promotion agreement for Treprostinil Injection. The company's cash and cash equivalents decreased slightly to $169.8 million.

Liquidia Corporation continued to report losses in Q4 2024 as it prepares for potential YUTREPIA approval. Revenue remained modest, impacted by pump availability constraints. The company strengthened its cash position through amended financing agreements.

Liquidia Corporation reported revenue of $4.4 million and a net loss of $23.2 million for the third quarter ended September 30, 2024. The company is awaiting final FDA approval for YUTREPIA, which is currently delayed until after the expiration of TYVASO DPI® exclusivity in May 2025 and is actively challenging this exclusivity.

Liquidia Corporation reported revenue of $3.7 million and a net loss of $27.9 million for the second quarter ended June 30, 2024. The company's cash and cash equivalents totaled $133.1 million as of June 30, 2024.

Liquidia Corporation reported a revenue of $3.0 million for Q1 2024, compared to $4.5 million in Q1 2023. The net loss was $40.9 million, or $0.54 per share, compared to a net loss of $11.7 million, or $0.18 per share, for the same period in the prior year. Cash and cash equivalents totaled $157.9 million as of March 31, 2024, compared to $83.7 million as of December 31, 2023.

Liquidia Corporation reported its full year 2023 financial results, with a net loss of $78.5 million. The company is preparing for the commercial launch of YUTREPIA following favorable court decisions and awaiting final FDA approval.

Liquidia Corporation reported revenue of $3.7 million and a net loss of $15.8 million for the third quarter ended September 30, 2023. The company is focused on advancing YUTREPIA and L606, with key regulatory and legal events anticipated.

Liquidia reported revenue of $4.8 million for the second quarter of 2023, an increase from $3.9 million in the same period last year. The net loss for the quarter was $23.5 million, or $0.36 per share, compared to a net loss of $9.4 million, or $0.15 per share, for the second quarter of 2022. Cash totaled $88.2 million as of June 30, 2023.

Liquidia Corporation reported a net loss of $11.7 million for Q1 2023, with revenue of $4.5 million, primarily from the Promotion Agreement. The company secured additional capital through a revenue interest financing agreement with HealthCare Royalty, receiving $31.8 million net proceeds.

Liquidia Corporation reported its full year 2022 financial results, with a focus on advancements in their legal and patent landscape, progress towards potential YUTREPIA launch, and strategic financial initiatives. The company highlighted key employee hires, clarified legal pathways with favorable patent rulings, and increased commitment to the Treprostinil Injection market through new collaborations. They fortified their financial position through strategic financing, ensuring they are well-positioned for the potential launch of YUTREPIA.

Liquidia reported revenue of $3.2 million and a net loss of $9.1 million for the third quarter of 2022. The company's cash totaled $98.3 million as of September 30, 2022. They are awaiting decisions on YUTREPIA™ (treprostinil) inhalation powder.

Liquidia Corporation reported its full-year 2021 financial results, highlighting the tentative FDA approval of YUTREPIA and the expansion of Treprostinil Injection use. The company is preparing to launch YUTREPIA in late 2022, pending final FDA approval.

Liquidia reported a revenue of $3.1 million for Q1 2021, a significant increase compared to no revenue in Q1 2020. The company's net loss decreased to $9.2 million from $14.8 million in the same period last year. They also reduced annual net spending by more than 40% and strengthened their financial position through a private placement and a new credit facility.

Liquidia Corporation reported its full-year 2020 financial results, highlighting the closure of the RareGen, LLC acquisition, executive team changes, and plans to respond to the LIQ861 CRL. The company is also focused on improving its balance sheet and cash spend, expecting positive contributions from Treprostinil Injection sales.